Winslow Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Winslow Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,244,976	Closed	-$277M	–	56
2020 Q2	$277M	Buy	2,244,976 +94,154	+4%	+$9.36M	1.35%	24
2020 Q1	$182M	Buy	+2,150,822	New	+$185M	1.11%	35
2016 Q1	–	Sell	-1,585,521	Closed	-$166M	–	138
2015 Q4	$166M	Buy	+1,585,521	New	+$166M	0.59%	59
2014 Q3	–	Sell	-104	Closed	-$6K	–	74
2014 Q2	$6K	Sell	104 -4,820,909	-100%	-$291M	﹤0.01%	69
2014 Q1	$329M	Buy	+4,821,013	New	+$355M	1.03%	50

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Winslow Capital Management's BMRN Position: Q3 2020 in Review

Winslow Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2020, closing a stake of 2,244,976 shares — an estimated $277M sold.

Winslow Capital Management first reported a position in BMRN in Q1 2014 and held it in 5 quarters. The position peaked at $329M in Q1 2014. 496 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

Winslow Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Winslow Capital Management sold 2,244,976 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $277M.
Winslow Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2014 and held it in 5 quarters.
Winslow Capital Management's BioMarin Pharmaceuticals position peaked at $329M in Q1 2014.
496 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on Winslow Capital Management's 13F filing for Q3 2020, filed 12 Nov 2020.